Ivosidenib

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (2)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
FDA (1)	IDH1 p.R132C	Myelodysplastic Syndromes	Ivosidenib
FDA (1)	IDH1 p.R132G	Myelodysplastic Syndromes	Ivosidenib
FDA (1)	IDH1 p.R132H	Myelodysplastic Syndromes	Ivosidenib
FDA (1)	IDH1 p.R132L	Myelodysplastic Syndromes	Ivosidenib
FDA (1)	IDH1 p.R132S	Myelodysplastic Syndromes	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib